Recombinant human erythropoietin (r-HuEpo) is now available to correct the anaemia of end stage renal failure. The clinical consequences of increasing the haemoglobin concentration in children on dialysis are incompletely documented; a placebo controlled study is essential when assessing subjective changes, for example in appetite or other aspects of quality of life.
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A single blind, placebo controlled crossover study in 11 children with end stage renal failure was performed to assess the clinical benefits resulting from correction of anaemia. Ten of the 11 children completed 36 weeks of the study and seven completed both 24 week limbs. Subcutaneous administration of r-HuEpo twice a week resulted in an increase in haemoglobin concentration, from 73 to 112 g/l. This was associated with an objective improvement in exercise tolerance, and a subjective improvement in physical performance and health, and better school attendance. No consistent effect was seen on appetite, growth, psychosocial functioning, biochemical control, or peritoneal dialysis efficiency. A small but clinically unimportant increase in systolic and diastolic blood pressure was seen in five children. One child on antihypertensive treatment required an increase in dosage during r-HuEpo while another child required a reduction in treatment.
These findings, together with the important cardiac benefits previously described during r-HuEpo treatment, support the use of r-HuEpo in all children with end stage renal failure and anaemia.
(Arch Dis Child 1993; 69: [580] [581] [582] [583] [584] [585] [586] A deficiency of erythropoietin is the single most important factor contributing to anaemia in end stage renal failure. Anaemia may be responsible for several of the clinical features of end stage renal failure in children, such as reduced exercise tolerance, fatigue, poor appetite, and impaired growth. With the characterisation and manufacture of recombinant human erythropoietin (r-HuEpo) in recent years it has become possible to correct anaemia and to assess which of these clinical features are attributable to anaemia. An none of these has been placebo controlled, making it impossible to interpret critically many of the effects ascribed to r-HuEpo. The present study was therefore designed as a single blind, placebo controlled crossover study in order to remove any bias that undoubtedly exists towards a new drug as heavily publicised as r-HuEpo and to assess the effects of r-HuEpo on quality of life, diet, exercise tolerance, and peritoneal dialysis efficiency in a group of children with end stage renal failure on long term peritoneal dialysis.
The cardiac benefits of r-HuEpo have been previously reported.5
Patients and methods Eleven children (nine boys, two girls) were enrolled into the study. 150  140  130  120  110  100  90  80  70  60  50  40  30   Group 2   0   24 48 weeks variables, however, were measured every 12 weeks throughout the study (2 minute walking distance, quality of life questionnaire, dietary intake) and it was therefore possible to include data from the three children who completed 36 weeks of the study but failed to complete both limbs. For these variables the mean of the measurements taken during each limb was used in the analysis. Blood pressure readings from these children were also included in the analysis. We felt that use of their data was justified because after 12 weeks of r-HuEpo their haemoglobin concentrations had already risen significantly (from 72 to 99 g/l) and within 12 weeks of stopping r-HuEpo their haemoglobin concentration had fallen to baseline values (from 103 to 67 g/l). The Wilcoxon signed rank sum test was used to assess the responses to the individual questions on the questionnaire while the group data is presented as the confidence interval for the difference between the treatment limbs, after summing the responses to related individual questions.
To analyse the weight, height, and mid-arm circumference data a within-patient comparison was made of the velocities during both limbs using a paired t test. A within-patient comparison is vital in view of the large variability in background growth velocities in different children. Lastly, the possibility of a transient effect of r-HuEpo on certain laboratory variables (white cell count, platelet count, serum r-HuEpo concentration) was assessed by looking separately at sequential data from the nine children who completed a 24 week limb of r-HuEpo.
Results

HAEMATOLOGICAL RESPONSE
The median haemoglobin rose from 73 g/l (range 42-81) at baseline to 112 g/l (range 95-142) after 24 weeks r-HuEpo (p<0-001; fig  1) . Five children developed evidence of iron deficiency but responded to iron supplementation; four responded to oral treatment but one child was intolerant of oral iron and required intravenous iron.10 Once the target haemoglobin had been reached it was possible to maintain it in four of the children on a once weekly dose regimen. At the end of the 24 The 2 minute walking distance increased during the r-HuEpo limb in the seven children in whom data from both limbs is avail- able (p=0-06; fig 2A) . Only three children attributed to r-HuEpo, though total energy intake tended to increase (p=0 19). Repeat analysis after adjustment for nasogastric feed intake produced a similar result. Individual parents, however, noticed a marked improvement in appetite during r-HuEpo which disappeared during placebo.
ANTHROPOMETRIC MEASUREMENT
No significant increase in weight (p= 0-2 1) or height velocity (p=0-21) was seen during r-HuEpo though again individual children showed an increased weight velocity during r-HuEpo relative to placebo. An increase in mid-arm circumference velocity was seen during r-HuEpo, though this failed to reach statistical significance (p=0 09). There was no comparable increase in triceps skinfold thickness though there was a greater variability in results, largely attributable to poor cooperation in some of the younger children who found the procedure uncomfortable. which documented an early increase in platelet count on r-HuEpo. These studies involved intravenous administration of r-HuEpo, which has a very different pharmacokinetic profile and achieves a much higher peak plasma concentration than subcutaneous r-HuEpo. '5 16 Important cardiac benefits of short term r-HuEpo treatment in this cohort of patients have already been reported,5 with a reduction in cardiac output and ventricular hypertrophy. In addition correction of anaemia is able to improve aspects of quality of life and to have a beneficial effect on exercise tolerance.
The specific questions within the quality of life questionnaire showing significant improvements after r-HuEpo were those reflecting less fatigue and breathlessness during exercise, improved general health, and better school attendance. In addition the final question, which attempted to summarise any overall change for the better on r-HuEpo, scored significantly better. Grouping related questions together confirmed an improvement in physical performance and health but failed to show any significant change in psychosocial, diet, school, or sleep behaviour. These findings are very similar to a large double blind study in adult dialysis patients looking at quality of life, which found an improvement in fatigue, strength, and physical symptoms without a consistent effect on psychological functioning or sleep disturbance.17 Although the majority of parents were able to correctly identify their child's r-HuEpo/placebo treatment order, two sets of parents were unable to do so despite a dramatic rise in haemoglobin, reflecting how well some children are able to compensate for severe anaemia. One of these children, however, had muscular dystrophy and clearly was not able to benefit from the improved physical performance seen in the other children.
Previous studies in children have documented improved exercise tolerance and an increase in peak oxygen consumption and ventilatory anaerobic threshold after r-HuEpo.3 12 18 The importance of including a control group was, however, shown in one of these studies in which the control group also showed a significant improvement in exercise tolerance over the 16 week observation period. 18 In our study both measures of exercise tolerance showed clear improvement after r-HuEpo, although the small number of children prevented this reaching statistical significance.
Previous uncontrolled studies in children have suggested an improvement in appetite associated with r-HuEpo,19 but we were unable to confirm this with either the record of dietary intake, the parental assessment of appetite on the questionnaire, or with changes in weight velocity. Individual parents, however, commented on marked improvements in appetite during r-HuEpo. In addition an increase in mid-arm circumference velocity was seen. It is possible therefore that a large study might be able to document an improvement in appetite and weight velocity. r-HuEpo did not result in any improvement in height velocity, confirming previous observations,20 and making it unlikely that anaemia contributes to the growth failure of end stage renal failure.
An increase in packed cell volume, coupled with a reduction in cardiac output, could theoretically reduce peritoneal dialysis efficiency by reducing effective plasma flow to the peritoneum. In practice our study, and the majority of studies in adults,2' 22 found no change in either dialysis efficiency or in ultrafiltrate volume, though others have reported an increase in ultrafiltrate,23 with either an increase23 or decrease24 in solute transport. In keeping with an unchanged dietary intake and peritoneal dialysis efficiency we found no change in plasma potassium, urea, creatinine, or phosphate concentrations during r-HuEpo treatment.
The development, or exacerbation, of hypertension is the commonest reported side effect of r-HuEpo administration, on occasions leading to encephalopathy.25 Patients with pre-existing hypertension at the start of treatment may be particularly at risk. During this study only one child with pre-existing hypertension required a marked increase in antihypertensive treatment during r-HuEpo. By contrast a minority of patients actually show a fall in blood pressure on r-HuEpo3 26; one child required a marked reduction in antihypertensive treatment during the r-HuEpo limb, probably as a result of a fall in cardiac output, followed by an increase in treatment during the placebo limb once his haemoglobin had fallen again. In the remaining children a small increase in both systolic and diastolic blood pressure was seen, though this did not necessitate any change in antihypertensive treatment. This increase in blood pressure was not evident in a previous analysis of this patient group,5 in which a single blood pressure reading only was taken at the time of echocardiography, stressing the importance of repeated measurement to minimise the inherent variability of blood pressure.
Although the bioavailability of r-HuEpo after subcutaneous injection is only 21-40% that of intravenous r-HuEpo,'5 16 its longer half life allows a more sustained action and produces a greater erythropoietic response for an equivalent dose.27 The absorption and elimination of subcutaneous r-HuEpo does not appear to change with long term treatment.28
The progressive increase in serum r-HuEpo concentration seen over the course of the r-HuEpo limb is compatible with published pharmacokinetic data in children.15 With a half life of 21 hours the serum concentration will remain significantly above the predose concentration for at least four days after a subcutaneous dose of r-HuEpo. If the bone marrow sensitivity to r-HuEpo remains unchanged, a progressive reduction in dose requirement would be predicted if administered twice weekly by subcutaneous injection.
In conclusion, correction of anaemia with r-HuEpo is associated with an objective improvement in exercise tolerance and a subjective improvement in physical fitness and health, including better school attendance. These benefits, together with the important cardiac benefits already reported, support the use of r-HuEpo in all children with end stage renal failure and anaemia.
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